Preclinical News and Research

RSS

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

Inovio Pharmaceuticals, Inc. today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the global industry as judged by a panel of global biotech industry stakeholders.

26 Mar 2014

HIV and Hepatitis C vaccines now closer to reality

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.

26 Mar 2014

Study explores dangers of switching from MDMA to mephedrone

Contrary to popular belief among recreational drug users, mephedrone has several important differences when compared with MDMA, commonly known as ecstasy. These differences mean that mephedrone could leave a user with acute withdrawal symptoms and indicate that it may have a higher potential for developing dependence than MDMA according to a study published in British Journal of Pharmacology.

26 Mar 2014

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

25 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Patrys Limited, a clinical stage biotechnology company, is pleased to provide an update on the development programme for anti-cancer product, PAT-LM1.

24 Mar 2014

Researchers developing new medication to tackle river blindness and elephantiasis

Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.

24 Mar 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new data from Professor Isabelle Leclercq of Université Catholique de Louvain (Belgium) demonstrating the curative effects of GFT505 in an experimental model of NASH associated with metabolic disorders.

20 Mar 2014

Systemic stem cell therapy reduces malignant mesothelioma growth

Systemic delivery of stem cells expressing an apoptosis-inducing protein can successfully incorporate into malignant pleural mesothelioma cells and subsequently induce their death, according to preclinical study findings.

19 Mar 2014

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the first patient has been dosed in a Phase 1 clinical trial of IGN523 in patients with relapsed or refractory acute myeloid leukemia (AML).

18 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

People who experience chronic sleep disturbance could face earlier onset of dementia, Alzheimer's

People who experience chronic sleep disturbance—either through their work, insomnia or other reasons—could face an earlier onset of dementia and Alzheimer's, according to a new pre-clinical study by researchers at Temple University.

18 Mar 2014

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Cytoplasmic expression of hypoxia inducible factor-2α is associated with poor prognosis in patients with clear cell renal cell carcinoma, study findings indicate.

17 Mar 2014

Antibe Therapeutics completes pre-clinical program for its lead product ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.

17 Mar 2014

Adherent stromal cells derived from human placenta improve tendon healing, shows study

According to Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS), although the findings of a recent study should be considered preliminary, adherent stromal cells derived from human placenta appear promising as a readily available cell source to aid tendon healing and regeneration.

17 Mar 2014

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

Derma Sciences, Inc., a tissue regeneration and burn care company focused on advanced wound care, today reported financial and operating results for the three months and year ended December 31, 2013.

14 Mar 2014

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

The UC Davis MIND Institute has been named an Intellectual and Developmental Disabilities Research Center, through a prestigious grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health - a distinction held by only a handful of neurodevelopmental centers nationwide committed to the diagnosis, prevention, treatment and amelioration of developmental disorders such as autism, fragile X syndrome and Down syndrome.

14 Mar 2014

CNIO scientist wins 2014 Stewart Rahr-PCF Young Investigator Award from Prostate Cancer Foundation

David Olmos, the Spanish National Cancer Research Centre's Head of the Prostate Cancer and Genitourinary Tumours Clinical Research Unit, has won the 2014 Stewart Rahr-PCF Young Investigator Award, endowed by the Prostate Cancer Foundation - the leading philanthropic organisation for cutting-edge research into prostate cancer.

14 Mar 2014

Preclinical News and Research

Inovio Pharmaceuticals receives three industry awards at World Vaccine Congress

HIV and Hepatitis C vaccines now closer to reality

Study explores dangers of switching from MDMA to mephedrone

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Patrys provides update on development programme for anti-cancer product, PAT-LM1

Researchers developing new medication to tackle river blindness and elephantiasis

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

New data shows curative effects of GFT505 in NASH associated with metabolic disorders

Systemic stem cell therapy reduces malignant mesothelioma growth

Igenica Biotherapeutics doses first patient in Phase 1 clinical trial of IGN523 in patients with AML

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

People who experience chronic sleep disturbance could face earlier onset of dementia, Alzheimer's

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Antibe Therapeutics completes pre-clinical program for its lead product ATB-346

Adherent stromal cells derived from human placenta improve tendon healing, shows study

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

CNIO scientist wins 2014 Stewart Rahr-PCF Young Investigator Award from Prostate Cancer Foundation

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics